Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-18-1175
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma

Hepatology
MedicineHepatology
2019English

Prospects to Improve Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors

Immunotherapy
OncologyAllergyImmunology
2016English

Nanoparticle Formulations of Histone Deacetylase Inhibitors for Effective Chemoradiotherapy in Solid Tumors

Biomaterials
Mechanics of MaterialsBiophysicsBiomaterialsBioengineeringCompositesNanoscienceNanotechnologyCeramics
2015English

The Role of Neoadjuvant Trials in Drug Development for Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2016English

Strategies to Improve the Implementation of Planning Mechanisms for Urban Housing Development in Selangor

Environment-Behaviour Proceedings Journal
2016English

Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

Occupational Health and Safety Professionals Strategies to Improve Working Environment and Their Self-Assessed Impact

Work
MedicineEnvironmentalPublic HealthRehabilitationOccupational Health
2012English

BIOMEDICINE: Picky Inhibitors for PI3K

Science
MultidisciplinaryPhilosophy of ScienceHistory
2005English

Immune Checkpoint Inhibitor Combinations in Solid Tumors: Opportunities and Challenges

Immunotherapy
OncologyAllergyImmunology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy